8-K current report · filed Jul 14, 2026

ANGIODYNAMICS INC (ANGO) 8-K Current Report: July 14, 2026

Item 7.01Item EX-99.1Item EX-99.2Item 2.02ANGO overview

Short answer

ANGIODYNAMICS INC (ANGO) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Fiscal fourth-quarter and full-year results announced for the period ended May 31, 2026.

ANGIODYNAMICS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal fourth-quarter and full-year results announced for the period ended May 31, 2026
  • Investor-relevant financial details contained in Exhibit 99.1, the accompanying earnings release

Item 7.01 · Regulation FD Disclosure

  • Exhibit 99.2 contains presentation slides covering fiscal fourth quarter and full year ended May 31, 2026
  • Investor focus: operating results, outlook and strategy details reside in the furnished presentation
  • Key risks include FDA actions, clinical trials, competition, inflation, tariffs, labor shortages and supply-chain constraints
  • Execution risks include product development, regulatory approvals, acquisitions, distributors, litigation and strategic initiatives

Item EX-99.1 · Exhibit EX-99.1

  • FY2026 revenue $320.2M, up 9.4%, led by Med Tech growth of 18.4% to $150.0M
  • Adjusted EBITDA $13.2M versus $7.6M, signaling improved operating leverage despite GAAP loss of $36.7M
  • NanoKnife sales rose 64.5% quarterly, supported by Medicare coverage effective July 5, 2026
  • Debt-free balance sheet with $53.9M cash and $3.1M full-year operating cash flow
  • FY2027 guidance: revenue $336.0M–$341.0M, Med Tech growth 12%–15%, adjusted EBITDA $13.0M–$16.0M

Item EX-99.2 · Exhibit EX-99.2

  • FY2026 revenue $320.2M, up 9.4%, led by Med Tech growth of 18.4% to $150.0M
  • Q4 revenue $86.6M, up 8.0%, with Med Tech up 16.7% and Med Device up 1.1%
  • NanoKnife FY2026 sales $33.1M, up 35.2%, while Auryon sales reached $66.9M, up 17.7%
  • Balance sheet strength: $53.9M cash, zero debt, and approximately $3.1M FY2026 operating cash flow
  • FY2027 guidance: revenue $336.0M-$341.0M, adjusted EBITDA $13.0M-$16.0M, adjusted EPS loss of $0.29-$0.24

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ANGIODYNAMICS INC 8-K filings

Get the next ANGO 8-K as it lands

Follow ANGO for push alerts, or ask the research agent what this filing means.